Skip to main content
SpringerLink
Log in

Recombinant Hirudin

Clinical Pharmacology and Potential Applications in Nephrology

  • Review Article
  • Published:
BioDrugs Aims and scope Submit manuscript

Abstract

The last decade has been characterised by the development of several anticoagulation methods as alternatives to the heparins. One of these is the antithrombin hirudin, which is now available on a large scale in the recombinant form. The application of hirudin as an anticoagulant in haemodialysis has been complicated by the decrease of its clearance in patients with renal failure. The half-life of hirudin is more than 30 times longer in haemodialysis patients than in healthy subjects. Therefore, at present, its use in the haemodialysis setting is essentially limited to heparin-induced thrombocytopenia (HIT). Hirudin has been used sporadically and with success in nonrenal failure patients with HIT and at least once on a regular basis in a haemodialysis patient. A starting dose between 0.08 and 0.15 mg/kg for the first dialysis, followed by 50% of this quantity during the following dialyses is recommended. Hirudin activity can be monitored by aiming for threshold activated partial thromboplastin time (aPTT) values between 60 and 90 seconds, with urgent dosage adaptations once aPTT rises above 100 to 120 seconds. Hirudin concentrations during dialysis should be maintained between 400 and 1000 μg/L, with determination by ecarin clotting time or chromogenic assays. At present, the use of hirudin is also limited by the absence of an effective antidote. In studies in humans, no enhanced removal of hirudin was observed during dialysis with large pore dialysers in contrast to earlier published animal studies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Vanholder R. Biocompatibility issues in hemodialysis. Clin Mat 1992; 10: 87–133

    Article  CAS  Google Scholar 

  2. Adams SL. The medicinal leech. A page from the annelids of internal medicine. Ann Intern Med 1988; 109: 399–405

    PubMed  CAS  Google Scholar 

  3. Haas G. Versuche der Blutauswaschung am Lebenden mit Hilfe der Dialyse. Klin Wochenschrift 1925; 4: 13–4

    Article  CAS  Google Scholar 

  4. Hirsh J. Heparin. N Engl J Med 1991; 324: 1565–74

    Article  PubMed  CAS  Google Scholar 

  5. Freedman MD. Pharmacodynamics, clinical indications, and adverse effects of heparin. J Clin Pharmacol 1992; 32: 584–96

    PubMed  CAS  Google Scholar 

  6. Hirsh J, Dalen JE, Deykin D, et al. Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1992; 102: S337–51

    Google Scholar 

  7. Hull RD, Raskob GE, Pineo GF, et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 1992; 326: 975–82

    Article  PubMed  CAS  Google Scholar 

  8. Salzman EW. Low-molecular-weight heparin and other new antithrombotic drugs. N Engl J Med 1992; 326: 1017–9

    Article  PubMed  CAS  Google Scholar 

  9. Vitoux JF, Mathieu JF, Roncato M, et al. Heparin-associated thrombocytopenia treatment with low molecular weight heparin. Thromb Haemost 1986; 55: 37–9

    PubMed  CAS  Google Scholar 

  10. Horellou MH, Conard J, Lecrubrier C, et al. Persistent heparin induced thrombocytopenia despite therapy with low molecular weight heparin. Thromb Haemost 1984; 51: 134

    PubMed  CAS  Google Scholar 

  11. Beijering JR, ten Cate H, Nurmohamed MT, et al. Anticoagulants and extracorporeal circuits. Semin Thromb Hemost 1997; 23: 225–33

    Article  PubMed  CAS  Google Scholar 

  12. Keeling DM, Richards EM, Baglin TP. Platelet aggregation in response to four low molecular weight heparins and the heparinoid ORG 10172 in patients with heparin-induced thrombocytopenia. Br J Haematol 1994; 86: 425–6

    Article  PubMed  CAS  Google Scholar 

  13. Verstraete M. Modulating platelet function with selective thrombin inhibitors. Haemostasis 1996; 26 Suppl. 4: 70–7

    Google Scholar 

  14. Schrör K. Antiplatelet drugs. A comparative review. Drugs 1995; 50: 7–28

    Article  PubMed  Google Scholar 

  15. Rydel TJ, Ravichandran KG, Tulinsky A, et al. The structure of a complex of recombinant hirudin and human α-thrombin. Science 1990; 249: 277–80

    Article  PubMed  CAS  Google Scholar 

  16. Glusa E. Pharmacology and therapeutic applications of hirudin, a new anticoagulant. Kidney Int 1998; 53 Suppl. 64: S54–6

    Google Scholar 

  17. Finkle CD, St Pierre A, Leblond L, et al. BCH-2763, a novel potent parenteral thrombin inhibitor, is an effective antithrombotic agent in rodent models of arterial and venous thrombosis — comparisons with heparin, r-hirudin, hirulog, inogatran and argatroban. Thromb Haemost 1998; 79: 431–8

    PubMed  CAS  Google Scholar 

  18. Yamabe H, Osawa H, Inuma H, et al. Thrombin stimulates production of transforming growth factor-beta by cultured human mesangial cells. Nephrol Dial Transplant 1997; 12: 438–42

    Article  PubMed  CAS  Google Scholar 

  19. Markwardt F. The development of hirudin as an antithrombotic drug. Thromb Res 1994; 74: 1–23

    Article  PubMed  CAS  Google Scholar 

  20. Pineo GF, Hull RD. Hirudin and hirudin analogues as new anticoagulant agents. Curr Opin Haematol 1995; 2: 380–5

    Article  CAS  Google Scholar 

  21. Kaiser B, Markwardt F. Antithrombotic and haemorrhagic effects of synthetic and naturally occurring thrombin inhibitors. Thromb Res 1986; 43: 613–20

    Article  PubMed  CAS  Google Scholar 

  22. Topol EJ. Novel antithrombotic approaches to coronary artery disease. Am J Cardiol 1995; 75: 27B–33B

    Article  PubMed  CAS  Google Scholar 

  23. Stringer KA, Lindenfield JA. Hirudins: antithrombin anticoagulants. Ann Pharmacother 1992; 26: 1535–40

    PubMed  CAS  Google Scholar 

  24. Anonymous. Hirudins: return of the leech? [editorial]. Lancet 1992; 340: 579-80

  25. Mirshahi M, Soria J, Soria C, et al. Evaluation of the inhibition by heparin and hirudin of coagulation activation during r-tPA-induced thrombolysis. Blood 1989; 74: 1025–30

    PubMed  CAS  Google Scholar 

  26. Meyer BJ, Badimon JJ, Chesebro JH, et al. Dissolution of mural thrombus by specific thrombin inhibition with r-hirudin. Comparison with heparin and aspirin. Circulation 1998; 97: 681–5

    Article  PubMed  CAS  Google Scholar 

  27. Agnelli G, Renga C, Weitz JI, et al. Sustained antithrombotic activity of hirudin after its plasma clearance: comparison with heparin. Blood 1992; 80: 960–5

    PubMed  CAS  Google Scholar 

  28. Heras M, Chesebro JH, Penny WJ, et al. Effects of thrombin inhibition on the development of acute platelet-thrombus deposition during angioplasty in pigs. Circulation 1989; 79: 657–65

    Article  PubMed  CAS  Google Scholar 

  29. Markwardt F, Hauptmann J, Nowak G, et al. Pharmacological studies on the antithrombotic action of hirudin in experimental animals. Thromb Haemost 1982; 47: 226–9

    PubMed  CAS  Google Scholar 

  30. Markwardt F, Nowak G, Stürzebecher J, et al. Clinico-pharmacological studies with recombinant hirudin. Thromb Res 1988; 52: 393–400

    Article  PubMed  CAS  Google Scholar 

  31. Nowak G, Bucha E, Gööck Th, et al. Pharmacology of r-hirudin in renal impairment. Thromb Res 1992; 66: 707–15

    Article  PubMed  CAS  Google Scholar 

  32. The GUSTO investigators. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation 1994; 90: 1631–7

    Article  Google Scholar 

  33. Hafner G, Fickenscher K, Friesen HJ, et al. Evaluation of an automated chromogenic substrate assay for the rapid determination of hirudin in plasma. Thromb Res 1995;77: 165–73

    Article  PubMed  CAS  Google Scholar 

  34. Pötzsch B, Hund S, Madiener K, et al. Monitoring of recombinant hirudin: assessment of a plasma-based ecarin clotting time assay. Thromb Res 1997; 86: 373–83

    Article  PubMed  Google Scholar 

  35. Pötzsch B, Madlener K, Seelig C, et al. Monitoring of r-hirudin anticoagulation during cardiopulmonary bypass — assessment of the whole blood ecarin clotting time. Thromb Haemost 1997; 77: 920–5

    PubMed  Google Scholar 

  36. Nowak G, Bucha E, Brauns I, et al. Anticoagulation with r-hirudin in regular haemodialysis with heparin-induced thrombocytopenia (HIT-II). The first long-term application of r-hirudin in a haemodialysis patient. Wien Klin Wochenschr 1997; 109: 354–8

    PubMed  CAS  Google Scholar 

  37. Nowak G. Therapeutic levels of recombinant hirudin [letter]. Haemostasis 1992; 22: 348–8

    PubMed  CAS  Google Scholar 

  38. Vanholder RC, Camez AA, Veys NM, et al. Recombinant hirudin: a specific thrombin inhibiting anticoagulant for hemodialysis. Kidney Int 1994; 45: 1754–9

    Article  PubMed  CAS  Google Scholar 

  39. van Wyk, Badenhorst PN, Luus HG, et al. A comparison between the use of recombinant hirudin and heparin during hemodialysis. Kidney Int 1995; 48: 1338–43

    Article  PubMed  Google Scholar 

  40. Walenga JM, Hoppensteadt D, Koza M, et al. Laboratory assays for the evaluation of recombinant hirudin. Haemostasis 1991; 21 Suppl. 1: 49–63

    Google Scholar 

  41. Vanholder R, Camez A, Veys N, et al. Pharmacokinetics of recombinant hirudin in hemodialyzed end-stage renal failure patients. Thromb Haemost 1997; 77: 650–5

    PubMed  CAS  Google Scholar 

  42. Zoldhelyi P, Webster MWI, Fuster V, et al. Recombinant hirudin in patients with chronic, stable coronary artery disease. Safety, half-life, and effect on coagulation parameters. Circulation 1993; 88: 2015–22

    Article  PubMed  CAS  Google Scholar 

  43. Esslinger HU, Haas S, Mauer R, et al. Pharmacodynamic and safety results of PEG-hirudin in healthy volunteers. Thromb Haemost 1997; 77: 911–9

    PubMed  CAS  Google Scholar 

  44. Markwardt F, Nowak G, Bucha E. Hirudin as anticoagulant in experimental hemodialysis. Haemostasis 1991; 21 Suppl. 1: 149–55

    Google Scholar 

  45. Meyer BH, Luus HG, Müller FO, et al. The pharmacology of recombinant hirudin, a new anticoagulant. S Afr Med J 1990; 78: 268–70

    PubMed  CAS  Google Scholar 

  46. Mehta RL. Anticoagulation strategies for continuous renal replacement therapies: what works? Am J Kidney Dis 1996; 28 Suppl. 3: S8–S14

    Article  Google Scholar 

  47. Neuhaus KL, von Essen R, Tebbe U, et al. Safety observations from the pilot phase of the randomized r-Hirudin for the Improvement of Thrombolysis (HIT-III) study. Circulation 1994; 90: 1638–42

    Article  PubMed  CAS  Google Scholar 

  48. Antman EM, TIMI 9A investigators. Hirudin in acute myocardial infarction: safety report from the thrombolysis and thrombin inhibition in myocardial infarction (TIMI) 9A trial. Circulation 1994; 90: 1624–30

    Article  PubMed  CAS  Google Scholar 

  49. Sobel BE. Intracranial bleeding, fibrinolysis, and anticoagulation. Causal connections and clinical implications. Circulation 1994; 90: 2147–52

    Article  PubMed  CAS  Google Scholar 

  50. Kelton JG, Hirsh J. Bleeding associated with antithrombotic therapy. Semin Hematol 1980; 17: 259–91

    PubMed  CAS  Google Scholar 

  51. Antman EM, TIMI 9B investigators. Hirudin in acute myocardial infarction. Thrombolysis and thrombin inhibition in myocardial infarction (TIMI) 9B trial. Circulation 1996; 94: 911–21

    Article  PubMed  CAS  Google Scholar 

  52. The Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO IIb) Angioplasty Substudy Investigators. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. N Engl J Med 1997; 336: 1621–8

    Article  Google Scholar 

  53. Fischer KG, Schollmeyer P. Adequate management of heparin-associated thrombocytopenia [letter]. Nephron 1998; 78: 112–3

    Article  PubMed  CAS  Google Scholar 

  54. Warkentin TE, Chong BH, Greinacher A. Heparin-induced thrombocytopenia: towards consensus. Thromb Haemost 1998; 79: 1–7

    PubMed  CAS  Google Scholar 

  55. Cancio LC, Cohen DJ. Heparin-induced thrombocytopenia and thrombosis. J Am Coll Surg 1998; 186: 76–91

    Article  PubMed  CAS  Google Scholar 

  56. Magnani HN. Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with Orgaran (Org 10172). Thromb Haemost 1993; 70: 554–61

    PubMed  CAS  Google Scholar 

  57. Greinacher A, Michels I, Mueller-Eckhardt HJ. Heparin-associated thrombocytopenia: the antibody is not heparin specific. Thromb Haemost 1992; 67: 545–9

    PubMed  CAS  Google Scholar 

  58. Ireland H, Lane DA, Flynn A, et al. The anticoagulant effect of heparinoid Org 10172 during hemodialysis: an objective assessment. Thromb Haemost 1986; 55: 271–5

    PubMed  CAS  Google Scholar 

  59. Kikta MJ, Keller MP, Humphrey PW, et al. Can low molecular weight heparins and heparinoids be safely given to patients with heparin-induced thrombocytopenia syndrome? Surgery 1993; 114: 705–10

    PubMed  CAS  Google Scholar 

  60. Hoppensteadt DA, Jeske WP, Walenga JM, et al. Efficacy of pentasaccharide in a dog model of hemodialysis. Thrombosis Res 1997; 88: 159–70

    Article  CAS  Google Scholar 

  61. Schmidt OH, Lang W. Heparin-induced thrombocytopenia with thromboembolic arterial occlusion treated with recombinant hirudin [letter]. N Engl J Med 1997; 337: 1389–9

    Article  PubMed  CAS  Google Scholar 

  62. Schiele F, Vuillemenot A, Kramarz P, et al. Use of recombinant hirudin as antithrombotic treatment in patients with heparininduced thrombocytopenia. Am J Haematol 1995; 50: 20–5

    Article  CAS  Google Scholar 

  63. Greinacher A, Völpel H, Poetzsch B. Recombinant hirudin (HBW 023) in the treatment of patients with heparin-associated thrombocytopenia (HAT) -a prospective study [abstract]. Thromb Haemost 1995; 73: 1456

    Google Scholar 

  64. Greinacher A, Völpel H, Pötzsch B. Recombinant hirudin in the treatment of patients with heparin-induced thrombocytopenia (HIT) [abstract]. Blood 1996; 88 Suppl. 1: 281a

    Google Scholar 

  65. Spinner S, Stoffler G, Fink E. Quantitative enzyme-linked immunosorbent assay (ELISA) for hirudin. J Immunol Methods 1986; 87: 79–83

    Article  PubMed  CAS  Google Scholar 

  66. Gygax D, Botta L, Ehrat M, et al. Immunoassays in monitoring biotechnological drugs. Ther Drug Monit 1996; 18: 405–9

    Article  PubMed  CAS  Google Scholar 

  67. Schenk JF, Glusa E, Radziwon P, et al. A recombinant hirudin (IK-HIR02) in healthy volunteers. I. Effects on coagulation parameters and bleeding time. Haemostasis 1996; 26: 140–9

    PubMed  CAS  Google Scholar 

  68. Mauricio I, Francischetti B, Monteiro RQ, et al. Identification of glycyrrhizin as a thrombin inhibitor. Biochem Biophys Res Commun 1997; 235: 259–63

    Article  CAS  Google Scholar 

  69. Johnson K, Choi Y, De Groot E, et al. Potential mechanisms for a proinflammatory vascular cytokine response to coagulation activation. J Immunol 1998; 160: 5130–5

    PubMed  CAS  Google Scholar 

  70. Anrather D, Millan MT, Palmetshofer A, et al. Thrombin activates nuclear factor-kappaB and potentiates endothelial cell activation by TNF. J Immunol 1997; 159: 5620–8

    PubMed  CAS  Google Scholar 

  71. Cirino G, Cicala C, Bucci M, et al. Factor Xa as an interface between coagulation and inflammation. J Clin Invest 1997; 99: 2446–51

    Article  PubMed  CAS  Google Scholar 

  72. Papapetropoulos A, Piccardoni P, Cirino G, et al. Hypotension and inflammatory cytokine gene expression triggered by factor Xa-nitric oxide signaling. Proc Natl Acad Sci USA 1998; 95: 4738–42

    Article  PubMed  CAS  Google Scholar 

  73. Matata BM, Wark S, Sundaram S, et al. In vitro contact phase activation with haemodialysis membranes: role of pharmaceutical agents. Biomaterials 1995; 16: 1305–12

    Article  PubMed  CAS  Google Scholar 

  74. Sundaram S, Irvine L, Courtney JM, et al. Modification of the influence of biomaterials on contact activation. Int J Artif Organs 1991; 14: 729–31

    PubMed  CAS  Google Scholar 

  75. van Wyk, Badenhorst PN, Kotzé HF: The effect of r-hirudin vs. heparin on blood-membrane interactions during hemodialysis. Clin Nephrol 1997; 48: 381–7

    PubMed  Google Scholar 

  76. Phaneuf MD, Szycher M, Berceli SA, et al. Covalent linkage of recombinant hirudin to a novel ionic poly(carbonate) urethane polymer with protein binding sites: determination of surface antithrombin activity. Artif Organs 1998; 22: 657–65

    Article  PubMed  CAS  Google Scholar 

  77. Römisch J, Diehl KH, Hoffmann D, et al. Comparison of in vitro and in vivo properties of rHirudin (HBW 023) and a synthetic analogous peptide. Haemostasis 1993; 23: 249–58

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Nephrology Section, University Hospital, De Pintelaan 185, B-9000, Gent, Belgium

    Raymond Vanholder

Authors
  1. Raymond Vanholder
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Annemieke Dhondt
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Raymond Vanholder.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vanholder, R., Dhondt, A. Recombinant Hirudin. BioDrugs 11, 417–429 (1999). https://doi.org/10.2165/00063030-199911060-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00063030-199911060-00006

Keywords

Search

Navigation